Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Background: An important emerging respiratory virus is the Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV had been associated with a high case fatality rate especially among severe cases.

Methods: This is a retrospective analysis of reported MERS-CoV cases between December 2016 and January 2019, as retrieved from the World Health Organization. The aim of this study is to examine the epidemiology of reported cases and quantify the percentage of healthcare workers (HCWs) among reported cases.

Results: There were 403 reported cases with a majority being men (n = 300; 74.4%). These cases were reported from Lebanon, Malaysia, Oman, Qatar, Saudi Arabia, and United Arab Emirates. HCWs represented 26% and comorbidities were reported among 71% of non-HCWs and 1.9% among HCWs (P < .0001). Camel exposure and camel milk ingestion were reported in 64% each, and the majority (97.8%) of those with camel exposures had camel milk ingestion. There were 58% primary cases and 42% were secondary cases. The case fatality rate was 16% among HCWs compared with 34% among other patients (P = .001). The mean age ± SD was 47.65 ± 16.28 for HCWs versus 54.23 ± 17.34 for non-HCWs (P = .001).

Conclusions: MERS-CoV infection continues to have a high case fatality rate and a large proportion of patients were HCWs. Further understanding of the disease transmission and prevention mainly in health care settings are needed.

© 2019 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Key Words: Middle East Respiratory Syndrome Coronavirus MERS MERS-CoV Healthcare workers transmission emerging infectious disease
cases were systematically reported and were reviewed including line listing. Statistical analysis was done using Minitab version 17 software (Minitab, State College, PA). A significant P value was considered for \( P < .05 \). Boxplots of time to specified events were generated as follows: lapsed time from onset of symptoms to hospitalization, onset of symptoms to confirmation of diagnosis, hospitalization to confirmation of diagnosis, and from onset of symptoms to death. These times (in days) were calculated based on the differences between the date of symptoms onset, date of hospitalization, date of diagnosis confirmation, and date of death (if this was the case).

We used publicly reported anonymized case-patient data reported to the World Health Organization, therefore, there was no requirement for informed consent or institutional review board approval.

RESULTS

In the study period, there was a total of 403 reported cases with a majority being men (n = 300; 74.4%). The mean age \( \pm SD \) was 52.5 \( \pm \) 17.3 years. These cases were reported from Lebanon (n = 1, 0.25%), Malaysia (n = 1, 0.25%), Oman (n = 8, 2%), Qatar (n = 3, 0.74%), Saudi Arabia (n = 382, 90.6%), and United Arab Emirates (n = 8, 2%). A line graph of the distribution of cases over time is shown in Figure 1.

Of all the cases, there were 105 (26%) among health care workers (HCWs). Comorbidities were reported among 214 (53%) cases with no available information on 9% of cases. Data on camel exposure were available for 245 cases and 157 (64%) had camel exposure. Although camel milk consumption was reported for 151 cases and 64% did have camel milk ingestion, the majority (97.8%) of those with camel exposures had camel milk ingestion. Classification of MERS-CoV infection was reported for 212 cases; 58% were primary cases and the others (42%) were secondary cases.

Figure 2 shows boxplot of time to specified events for lapsed time from onset of symptoms to hospitalization, onset of symptoms to diagnosis, and onset to death. The case fatality rate was 29.3% in general, and there was a significant difference in the case fatality rates between HCWs (16%) and others (34%) (\( P = .001 \)). The presence of comorbidities was 71% among non-HCWs and 1.9% among HCWs (\( P < .0001 \)). In addition, the mean age \( \pm SD \) was 47.65 \( \pm \) 16.28 for HCWs versus 54.23 \( \pm \) 17.34 for non-HCWs (\( P = .001 \)).

Fig 1. Line graph showing monthly Middle East respiratory syndrome coronavirus cases from December 2016 to January 2019.

Fig 2. Boxplot of time to specified events and was calculated as follows: lapsed time from onset of symptoms to hospitalization, onset of symptoms to confirmation of diagnosis, hospitalization to confirmation of diagnosis, and from onset of symptoms to death. These times (in days) were calculated based on the differences between the date of symptoms onset, date of hospitalization, date of diagnosis confirmation, and date of death (if this was the case). confirm, confirmation; hosp, hospitalization; TAT, turnaround time.
A comparison between primary and secondary cases is shown in Table 1 and Figure 3. Primary cases were older with higher comorbidities, male sex, and case fatality rate. However, secondary cases were more likely to be HCWs.

**DISCUSSION**

The total reported cases in the last 2 years was 403 and constitutes 17.6% of all reported cases. These were reported from 6 countries: Lebanon, Malaysia, Oman, Qatar, Saudi Arabia, and United Arab Emirates. However, there was a continued decline in the monthly number of cases. It had also been shown that there was a negative trend and reduction in monthly numbers of primary MERS-CoV cases over a 3-year period from 2015-2017.11 This continued reduction in the number of cases is primarily owing to containments of the cases and prevention of health care–associated outbreaks.12 It was also projected that primary MERS-CoV cases would decrease to 5 cases in the spring of 2019.11

In the current analysis, a large proportion of cases were among HCWs. The amplification of MERS-CoV is well known to occur in health care settings as the hallmark of its transmission.15 In previous studies, HCWs represent an important fraction of people with MERS-CoV infection with a reported rate of 14%-64%.13,20,26 HCWs with MERS-CoV infection were either asymptomatic or had mild disease, and fatal cases were described.27 Transmission of MERS-CoV among HCWs was reported to result from asymptomatic HCWs.27

The presence of comorbidities was seen in 53% of patients in the current study, and it was reported that severe disease tends to occur in people with comorbid diseases and the elderly.28 The case fatality rate in the current study is 29.3%, and seems to be within the previously reported rates of 28%-64%.29,30 However, higher case fatality rate was attributed to the inclusion of symptomatic and critical ill patients.30 and the identification of more asymptomatic cases resulted in reduction in the case fatality rate from 64%-30%.6,20,31,32 HCWs with MERS-CoV had a lower fatality rate of 7%.33

Of those with known camel exposure in the study, 64% had camel exposure mainly as camel milk ingestion. There are multiple studies describing the relationship between camel exposure and MERS-CoV infection. The rate of camel exposure was variable in different studies from 1.7% in a study of 70 cases to 4.3% in a study of 161.32 In a study of 348 primary MERS-CoV cases, 191 (54.9%) had contact with dromedaries.34 It is known that the calving season for dromedaries is November and March.31,35-37 In 1 study, the prevalence of MERS-CoV was higher among camels in the winter time (71.5%) than the summer time (6.2%).38 However, the current cases occurred at a high number in May and June 2017 and not the winter time.

The study showed interesting points in relation to primary cases in that these patients were older and had higher case fatality rate and comorbidities. The finding is similar to previous analysis of MERS-CoV cases.34 These differences reflect different risks as primary cases occur frequently among camel exposures and in the community, whereas secondary cases occur mainly in the health care settings with a high rate of young HCWs.

### Table 1

|                        | Primary cases | Secondary cases | Pvalue |
|------------------------|--------------|----------------|--------|
| Number                 | 136          | 100            |        |
| Age mean ± SD          | 57.5 ± 16.3  | 24.8 ± 15.8    | <0.0001|
| Male, N (%)            | 114 (83)     | 54 (54)        | <0.0001|
| Health care workers, N (%) | 1 (0.74) | 42 (42)        | <0.0001|
| Comorbidities, N (%)   | 108 (82)     | 31 (45)        | <0.0001|
| Camel exposure, N (%)  | 79/85 (92)   | 77/107 (72)    | <0.0001|
| Death, N (%)           | 51 (37.5)    | 14 (14)        | <0.0001|

Fig 3. Interval plot of age versus exposure to MERS-CoV cases. CI, confidence interval; MERS-CoV, Middle East respiratory syndrome coronavirus.
CONCLUSIONS

There remains a large number of MERS-CoV in 2017 and 2018, with a decreasing number over time. HCWs constitute a high-risk group owing to continued exposure at health care settings. Primary care providers are at a high risk of contracting MERS-CoV due to continued exposure at health care settings. Continued vigilance and identification of suspected cases are needed to prevent transmission.

References

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
2. Al-Tawfiq JA, Gauert P. Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV) infection: extent and implications for infection control: a systematic review. Travel Med Infect Dis 2019;27:27-32.
3. Al-Tawfiq JA, Memish ZA. Drivers of MERS-CoV transmission: what do we know? Expert Rev Respir Med 2016;10:331-4.
4. Harcourt JL, Rudoler N, Tamin A, Lesher E, Razi M, Giladi M, et al. The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel, Zoonoses Public Health 2018;65:749-54.
5. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, et al. Hospital associated outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013;369:407-16.
6. Memish ZA, Al-Tawfiq JA, Alhakeem RF, Assiri A, Alharby KD, Almahallawi MS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): a cluster analysis with implications for global management of suspected cases. Travel Med Infect Dis 2015;13:311-4.
7. Ko J-H, Park GE, Lee JY, Lee JY, Cho SY, Ha YE, et al. Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect 2016;73:468-75.
8. Park MH, Kim HR, Choi DH, Sun HJ, Kim JH. Emergency cesarean section for a patient with respiratory failure due to Middle East respiratory syndrome. J Obstet Gynaecol Res 2015;41:971-4.
9. Al-Tawfiq JA, Al-Rabieh AA, Hinedi K. Influenza is more common than Middle East respiratory syndrome coronavirus (MERS-CoV) among hospitalized adult Saudi patients. Travel Med Infect Dis 2017;20:56-60.
10. World Health Organization. Middle east respiratory syndrome coronavirus (MERS-CoV), WHO 2017. Available from: http://www.who.int/emergencies/mers-cov/en/, Accessed April 30, 2017.
11. Al-Tawfiq JA, Memish ZA. Lack of seasonal variation of Middle East respiratory syndrome coronavirus (MERS-CoV), Travel Med Infect Dis 2019;27:125-6.
12. Al-Tawfiq JA, Awaarther PC. Healthcare-associated infections: the hallmark of the Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect 2019;101:20-9.
13. Al-Tawfiq JA, Perl TM. Middle East respiratory syndrome coronavirus in healthcare settings. Curr Opin Infect Dis 2015;28:392-6.
14. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS-CoV global summary and assessment of risk global summary. Available from: http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1, Accessed September 14, 2017.
15. Alnani KH, Killerby ME, Biggs HM, Abedi GR, Jokhdar H, Alsharef AA, et al. Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017. Infect Control Hosp Epidemiol 2019;40:79-86.
16. Amer H, Alqahtani AS, Alaklobi F, Altayeb J, Memish ZA. Healthcare worker exposure to Middle East respiratory syndrome coronavirus (MERS-CoV): revision of screening strategies urgently needed. Int J Infect Dis 2018;71:113-6.
17. Amer H, Alqahtani AS, Alzoman H, Aljerian N, Memish ZA. Unusual presentation of Middle East respiratory syndrome coronavirus leading to a large outbreak in Riyadh during 2017. Am J Infect Control 2018;46:1022-5.
18. Drosten C, Muth D, Corman VM, Huisain R, Al Masri M, HajOmar W, et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015;60:369-77.
19. Al-Abdellat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a sero-logic, epidemiologic, and clinical description. Clin Infect Dis 2014;59:1225-33.
20. Memish ZA, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus infection control: the missing piece? Am J Infect Control 2014;42:1258-60.
21. Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugtri H, Aloraini MS, et al. 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. N Engl J Med 2015;372:846-54.
22. Fagbo SF, Skakni L, Chu DKW, Garbati MA, Joseph M, Peiris M, et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. Emerg Infect Dis 2015;21:1981-8.
23. Al-Tawfiq JA, Hinedi K, Memish ZA. Systematic review of the prevalence of Mycobacterium tuberculosis resistance in Saudi Arabia. J Chemother 2015;27:378-82.
24. Al Hosani FI, Pringle K, Al Mulla M, Kim L, Pham H, Alami NN, et al. Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014. Emerg Infect Dis 2016;22:1162-8.
25. Ballas HY, Alnazi TH, Alshamrani MM, Baffoe-Bonnie H, Arabi Y, Hijazi R, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 2016;37:1147-55.
26. Alfaraj SH, Al-Tawfiq JA, Gautret P, Alnazi MG, Asiri AY, Memish ZA. Evaluation of visual triage for screening of Middle East respiratory syndrome coronavirus patients. New Microbes New Infect 2018;26:49-52.
27. Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Alnani M, Alzahrani N, Memish ZA. Middle East respiratory syndrome coronavirus transmission among health care workers: implications for infection control. Am J Infect Control 2018;46:165-8.
28. Aly M, Eliboh M, Alzayer M, Aljuhani S, Balthal K. Occurrence of the Middle East respiratory syndrome coronavirus (MERS-CoV) across the Gulf Cooperation Council countries: four years update. PLoS One 2017;12:e0183850.
29. Al-Tawfiq JA, Alfaraj SH, Altuwaijri TA, Memish ZA. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J Infect 2017;75:375-89.
30. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus intermittent positive cases: implications for infection control. Am J Infect Control 2019;47:290-3.
31. Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. Infect Drug Resist 2014;7:281-7.
32. WHO Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5:
33. Liu S, Chan T-C, Chu Y-T, Wu JT-S, Geng X, Zhao N, et al. Comparative epidemiology of human infections with Middle East respiratory syndrome and severe acute respiratory coronaviruses among healthcare personnel. PLoS One 2016;11:e014988.
34. Conzade R, Grant R, Malik MR, Elkholy A, Elhakim M, Sambourn D, et al. Reported and direct indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases. Viruses 2018;10:425.
35. Khalafalla AI, Altuwaer PC, Dababat AH, Al-Busadah KA, Erdman DD. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis 2015;21:1153-8.
36. Gossner C, Danielson N, Gervelmeyer A, Berthe F, Faye B, Kaaska Aaslav K, et al. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection. Zoonoses Public Health 2016;63:1-9.
37. Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Li M, et al. Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013;18:20639.
38. Kasem S, Qasim I, Al-Dowerji A, Hashim O, Alkarkar A, Abu-Obieda A, et al. The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in livestock and temporal relation to locations and seasons. J Infect Public Health 2018;11:884-8.